These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 6174204

  • 21. A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma.
    Chang AY, Bennett JM, Pandya KJ, Asbury R, McCune C.
    Am J Clin Oncol; 1989 Aug; 12(4):358-60. PubMed ID: 2474242
    [Abstract] [Full Text] [Related]

  • 22. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 23. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS.
    Lancet Oncol; 2012 Dec 01; 13(12):1210-7. PubMed ID: 23142059
    [Abstract] [Full Text] [Related]

  • 24. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May 01; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 25. [Cancer of the prostate: subcapsular orchiectomy].
    Cukier J, Rivain T.
    Bull Cancer; 1985 May 01; 72(6):543-8. PubMed ID: 4092105
    [Abstract] [Full Text] [Related]

  • 26. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
    Smith IE, Harris AL, Morgan M, Gazet JC, McKinna JA.
    Cancer Res; 1982 Aug 01; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
    [Abstract] [Full Text] [Related]

  • 27. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
    Osborne CK, Drelichman A, Von Hoff DD, Crawford ED.
    Cancer Treat Rep; 1983 Dec 01; 67(12):1133-5. PubMed ID: 6652630
    [Abstract] [Full Text] [Related]

  • 28. Tamoxifen therapy in premenopausal patients with metastatic breast cancer.
    Pritchard KI, Thomson DB, Myers RE, Sutherland DJ, Mobbs BG, Meakin JW.
    Cancer Treat Rep; 1980 Dec 01; 64(6-7):787-96. PubMed ID: 7427962
    [Abstract] [Full Text] [Related]

  • 29. Tamoxifen in the palliative treatment of advanced breast cancer. A clinical review.
    Orr JD, Macdonald JA, Thomson JW.
    J R Coll Surg Edinb; 1979 May 01; 24(3):141-7. PubMed ID: 88517
    [No Abstract] [Full Text] [Related]

  • 30. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K, Lehnert M, Stettner H, Hubmer G.
    Eur Urol; 1997 May 01; 32 Suppl 3():81-5. PubMed ID: 9267791
    [Abstract] [Full Text] [Related]

  • 31. Tamoxifen therapy in recurrent epithelial ovarian carcinoma.
    Weiner SA, Alberts DS, Surwit EA, Davis J, Grosso D.
    Gynecol Oncol; 1987 Jun 01; 27(2):208-13. PubMed ID: 3570058
    [Abstract] [Full Text] [Related]

  • 32. Hormonal therapy for metastatic male breast cancer.
    Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G.
    Arch Intern Med; 1983 Feb 01; 143(2):237-40. PubMed ID: 6824391
    [Abstract] [Full Text] [Related]

  • 33. Tamoxifen therapy in premenopausal women with metastatic breast cancer.
    Planting AS, Alexieva-Figusch J, Blonk-vdWijst J, van Putten WL.
    Cancer Treat Rep; 1985 Apr 01; 69(4):363-8. PubMed ID: 3995508
    [Abstract] [Full Text] [Related]

  • 34. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
    Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B, Toner GC.
    Am J Clin Oncol; 2009 Aug 01; 32(4):338-41. PubMed ID: 19363437
    [Abstract] [Full Text] [Related]

  • 35. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
    Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G, Shafik A.
    Cancer Res; 1982 Aug 01; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
    [Abstract] [Full Text] [Related]

  • 36. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A.
    Urology; 2005 Jan 01; 65(1):126-30. PubMed ID: 15667877
    [Abstract] [Full Text] [Related]

  • 37. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.
    Slovin SF, Kelly WK, Wilton A, Kattan M, Myskowski P, Mendelsohn J, Scher HI.
    Clin Genitourin Cancer; 2009 Oct 01; 7(3):E77-82. PubMed ID: 19815486
    [Abstract] [Full Text] [Related]

  • 38. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M, ARADES study group.
    Lancet Oncol; 2014 Aug 01; 15(9):975-85. PubMed ID: 24974051
    [Abstract] [Full Text] [Related]

  • 39. Tamoxifen therapy of epithelial ovarian cancer.
    Shirey DR, Kavanagh JJ, Gershenson DM, Freedman RS, Copeland LJ, Jones LA.
    Obstet Gynecol; 1985 Oct 01; 66(4):575-8. PubMed ID: 4047546
    [Abstract] [Full Text] [Related]

  • 40. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
    Bui NB, Chauvergne J, Brunet R, Richaud P, Hoerni B, Lagarde C, Le Guillou M.
    Bull Cancer; 1986 Oct 01; 73(1):65-7. PubMed ID: 3779124
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.